PURPOSE: To evaluate the prevalence of acute nausea and emesis during concurrent chemoradiotherapy (CRT) with emphasis on the influence of patient- and treatment-related risk factors and prophylactic antiemetic medication. PATIENTS AND METHODS: A total of 335 patients treated with different intravenous standard chemoradiotherapy protocols in the inpatient setting were included in this retrospective study. Acute nausea and emesis, scored according to the CTC (version 3.0) criteria, were evaluated during 821 chemotherapy cycles. Side effects were correlated with patient-, tumor-, and treatment-related parameters. RESULTS: Overall, at least one episode of acute nausea occurred in 48% of the patients and at least one episode of vomiting occurred in 25% of patients. The emetogenic level of the applied chemotherapy protocol was the most significant risk factor for developing nausea and emesis (p < 0.0001). The site of irradiation - namely the thorax (p = 0.0110) and head and neck (p = 0.0415) - was also confirmed as a risk factor. Patient-related parameters, e.g., female gender (p = 0.0003), young age (< 40 years; p = 0.0029), weight loss > 5% (p = 0.0004), and the presence of a percutaneous endoscopic gastrostomy (PEG; p = 0.0071), were associated with higher rates of nausea and emesis, while a history of alcohol abuse showed a protective effect (p = 0.0553). In high emetogenic chemotherapy protocols, prophylaxis with 5-HT3 antagonist plus dexamethasone was superior to 5-HT3 antagonist alone (p = 0.0383). CONCLUSION: Future studies should evaluate more effective prophylaxis protocols in CRT in order to reduce the high rates of nausea and emesis.
PURPOSE: To evaluate the prevalence of acute nausea and emesis during concurrent chemoradiotherapy (CRT) with emphasis on the influence of patient- and treatment-related risk factors and prophylactic antiemetic medication. PATIENTS AND METHODS: A total of 335 patients treated with different intravenous standard chemoradiotherapy protocols in the inpatient setting were included in this retrospective study. Acute nausea and emesis, scored according to the CTC (version 3.0) criteria, were evaluated during 821 chemotherapy cycles. Side effects were correlated with patient-, tumor-, and treatment-related parameters. RESULTS: Overall, at least one episode of acute nausea occurred in 48% of the patients and at least one episode of vomiting occurred in 25% of patients. The emetogenic level of the applied chemotherapy protocol was the most significant risk factor for developing nausea and emesis (p < 0.0001). The site of irradiation - namely the thorax (p = 0.0110) and head and neck (p = 0.0415) - was also confirmed as a risk factor. Patient-related parameters, e.g., female gender (p = 0.0003), young age (< 40 years; p = 0.0029), weight loss > 5% (p = 0.0004), and the presence of a percutaneous endoscopic gastrostomy (PEG; p = 0.0071), were associated with higher rates of nausea and emesis, while a history of alcohol abuse showed a protective effect (p = 0.0553). In high emetogenic chemotherapy protocols, prophylaxis with 5-HT3 antagonist plus dexamethasone was superior to 5-HT3 antagonist alone (p = 0.0383). CONCLUSION: Future studies should evaluate more effective prophylaxis protocols in CRT in order to reduce the high rates of nausea and emesis.
Authors: R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Jørn Herrstedt; Jim M Koeller; Fausto Roila; Paul J Hesketh; David Warr; Cynthia Rittenberg; Mario Dicato Journal: Support Care Cancer Date: 2004-11-23 Impact factor: 3.603
Authors: Arash Naeim; Sydney M Dy; Karl A Lorenz; Homayoon Sanati; Anne Walling; Steven M Asch Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson Journal: Support Care Cancer Date: 2008-06-05 Impact factor: 3.603
Authors: R de Wit; J Herrstedt; B Rapoport; A D Carides; J Guoguang-Ma; M Elmer; C Schmidt; J K Evans; K J Horgan Journal: Eur J Cancer Date: 2004-02 Impact factor: 9.162
Authors: Juan Bayo; Paula J Fonseca; Susana Hernando; S Servitja; A Calvo; S Falagan; Estefanía García; Iria González; María José de Miguel; Quionia Pérez; Ana Milena; Antonio Ruiz; Agustí Barnadas Journal: Clin Transl Oncol Date: 2012-06 Impact factor: 3.405
Authors: Michael Poon; Kristopher Dennis; Carlo DeAngelis; Hans Chung; Jordan Stinson; Liying Zhang; Gillian Bedard; Marko Popovic; Nicholas Lao; Natalie Pulenzas; Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2014-01-12 Impact factor: 3.603
Authors: Canhua Xiao; Alexandra Hanlon; Qiang Zhang; Benjamin Movsas; Kian Ang; David I Rosenthal; P Félix Nguyen-Tan; Harold Kim; Quynh Le; Deborah Watkins Bruner Journal: Cancer Date: 2013-12-11 Impact factor: 6.860
Authors: Esengul Kocak-Uzel; G Brandon Gunn; Rivka R Colen; Micheal E Kantor; Abdallah S R Mohamed; Sara Schoultz-Henley; Paniyotis Mavroidis; Steven J Frank; Adam S Garden; Beth M Beadle; William H Morrison; Jack Phan; David I Rosenthal; Clifton D Fuller Journal: Radiother Oncol Date: 2014-04-17 Impact factor: 6.280
Authors: Kilian Schiller; Hanno Martin Specht; Bernhard Haller; Daniela Hallqvist; Michal Devecka; Aaron Becker von Rose; Stephanie Elisabeth Combs; Steffi Pigorsch Journal: Radiat Oncol Date: 2017-07-04 Impact factor: 3.481